Pfizer’s generic deals don’t violate competition law, says Australian court

31-05-2018

Pfizer’s generic deals don’t violate competition law, says Australian court

MarkRubens / iStockphoto.com

A court has rejected an appeal by the Australian Competition and Consumer Commission (ACCC), in a decision which confirmed that deals made by Pfizer in relation to generic cholesterol-lowering medication do not constitute a misuse of its market power.


Pfizer, Federal Court of Australia, ACCC, atorvastatin, Lipitor, patent expiry, anti-competition, market competition, generic competition, drug sales

LSIPR